Corteva 8-K

RestructuringImpairment / chargeLegal / investigationDeal completedEarningsDebt financing

Vylor Seed spin-off completed, leaving Crop Protection as a standalone business with new financing and independent-company costs.

Filed 2026-10-01 17:25 ET

Summary

Completion of Corteva’s Seed-business spin-off, with audited 2025 and interim 2026 Crop Protection results and pro forma standalone figures. The separation was completed on 10/01/2026, distributing Vylor to Corteva shareholders; New Corteva’s financial statements present the Crop Protection business as a standalone company. Historical results are carve-out figures, while the pro forma statements estimate standalone performance and financing.

Key Figures

Metric FY2025 FY2024 Y/Y
Net sales $7.84B $7.55B +3.8%
Income from continuing operations after income taxes (GAAP) $669M $(81.0)M n/m
Operating EBITDA (non-GAAP) $1.49B $1.32B +12.9%
Net income attributable to New Corteva $560M $(35.0)M n/m
Operating cash flow $459M $193M +138%
Metric H1 2026 H1 2025 Y/Y
Net sales $3.85B $3.73B +3.2%
Income from continuing operations after income taxes (GAAP) $211M $318M -33.6%
Operating EBITDA (non-GAAP) $815M $731M +11.5%
Net income attributable to New Corteva $152M $236M -35.6%
Operating cash flow $(965)M $80M n/m
  • H1 2026 operating cash flow included a $1.126B pension contribution; total discretionary contributions were ≈$1.5B, including $399M paid in July. Cash at 6/30/2026 was $1.90B, with short-term borrowings of $3.09B.
  • H1 earnings were pressured by other income/expense shifting from $123M income to $(94)M expense, including estimated litigation settlements. The $229M of pre-tax significant items included $121M of litigation settlement expense and $108M of restructuring charges.
  • Pro forma standalone results: FY2025 net sales $7.59B and net income attributable to New Corteva $523M; H1 2026 net sales $3.77B and attributable income $161M. After estimated standalone-cost adjustments, GAAP attributable income was $495M and $146M, respectively, with EPS of $0.73 and $0.22. Pro forma operating EBITDA (non-GAAP) was $1.298B and $738M; adjusted pro forma operating EBITDA was $1.267B and $721M.
  • Pro forma capitalization reflects $3.499B of cash from Vylor and a $3.761B reduction in debt principal, net of $700M of new long-term debt. New Corteva issued $700M principal amount of 6.000% senior notes due August 2036, for general corporate purposes including commercial-paper repayment; $1.439B principal amount of EIDP notes was exchanged and is no longer New Corteva debt.
  • Crop Protection operations restructuring charges are expected to total $720M-$783M, with $375M-$418M in cash payments; $229M had been paid through H1 2026, and completion is expected by end-2028. Separate 2026 restructuring actions are expected to cost $40M-$50M, all severance, with substantially all cash payments in 2026 and completion by December 2026.
  • PFAS settlements include New Jersey payments of $875M over 25 years (≈$500M net present value at 8%) and a North Carolina settlement of $455M over 15 years, with Corteva’s share ≈$66M. Corteva recorded a $72M pre-tax loss ($58M after-tax) for its New Jersey share in Q2 2025; the North Carolina settlement also requires Corteva and DuPont to guarantee Chemours’ share and provide a reserve facility capped at $135M.

Guidance

No guidance in this filing.

Investor Takeaways

  • Track New Corteva’s results against the pro forma standalone figures as independent-company costs and commercial arrangements with Vylor take effect.
  • Watch court approval of the FTC and private antitrust settlements, along with the Indiana states’ request to block further asset transfers, including dividends and share repurchases.
  • PFAS litigation remains a material uncertainty; the first AFFF personal-injury bellwether trial is expected to be scheduled for 2027.

The summary is written by an AI model reading the filing.

Model 005 · prompt 01d34d48e3

Feedback